<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="article-commentary" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0213264</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1117</journal-id>
<journal-id journal-id-type="nlm-ta">Biol Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Biol. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Biological psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-3223</issn>
<issn pub-type="epub">1873-2402</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27079494</article-id>
<article-id pub-id-type="pmc">4924879</article-id>
<article-id pub-id-type="doi">10.1016/j.biopsych.2016.03.1045</article-id>
<article-id pub-id-type="manuscript">NIHMS797203</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>N</italic>-Methyl-D-Aspartate Receptors, Ketamine, and Rett Syndrome: Something Special on the Road to Treatments?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Katz</surname>
<given-names>David M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Menniti</surname>
<given-names>Frank S.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mather</surname>
<given-names>Robert J.</given-names>
</name>
</contrib>
<aff id="A1">Departments of Neurosciences and Psychiatry (DMK), Case Western Reserve University School of Medicine, Cleveland, Ohio; Mind-Immune Therapeutics (FSM), Kingston, Rhode Island; and Neuroscience Innovative Medicines and Early Development Biotech Unit (RJM), AstraZeneca, Cambridge, Massachusetts</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Address correspondence to David M. Katz, Ph.D., Case Western Reserve University School of Medicine, Department of Neurosciences, 10900 Euclid Avenue, Cleveland, OH 44106; <email>david.katz@case.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>23</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<day>1</day>
<month>5</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>28</day>
<month>6</month>
<year>2016</year>
</pub-date>
<volume>79</volume>
<issue>9</issue>
<fpage>710</fpage>
<lpage>712</lpage>
<!--elocation-id from pubmed: 10.1016/j.biopsych.2016.03.1045-->
<related-article ext-link-type="pmid" id="ra1" related-article-type="commentary-article" xlink:href="17289941" xlink:type="simple"></related-article>
</article-meta>
</front>
</article>
</pmc-articleset>